Cancer Drugs Move from IV to SC | Predictions for 2025
A prediction for 2025 by Marci Chodroff, M.D., vice president of Medical Affairs at Prime Therapeutics and Managed Healthcare Executive editorial advisory board member.
According to the American Cancer Society, new cancer cases were expected to exceed the 2 million mark in 2024. With the rapid rise in the incidence of cancer, it is important to consider how the delivery of oncology treatment could be improved to meet the patient where they are. In 2025, I believe we may begin to see greater patient-centric approaches to treatment.
Chodroff
One example occurred in September 2024 when the checkpoint inhibitor Tecentriq Hybreza [atezolizumab and hyaluronidase] was approved for subcutaneous (SC) administration over seven minutes. Intravenous Tecentriq is infused over 30 minutes. Switching to the SC dosage form may improve patient experience overall to provide a less invasive and more convenient method for a nurse to administer the medication in a patient’s home instead of the doctor’s office. This transition of care could reduce the out-of-pocket expenses and time related to travel. In addition, treatment in the home decreases patient exposure to communicable diseases that may further compromise their immune system. The movement to in-home administration also frees up provider infusion chairs and in-office appointments for patients who require closer monitoring.
Opdivo [nivolumab] is another checkpoint inhibitor that may soon be available, and SC Keytruda [pembrolizumab] is in phase 3 trials. Although the conversion from IV to SC is not new, the high utilization of this drug class makes this simple change impactful and will drive positive change for oncology patients.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Why Better Data and Awareness Matters for Medicaid Work Requirements
April 17th 2025With policymakers considering work requirements for Medicaid eligibility, Jennifer Haley, principal research associate in the Health Policy Division at the Urban Institute, said it’s more important than ever to understand how those changes could unintentionally cause harm, particularly when data systems fall short and public awareness is limited.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Medicaid Expansion Linked To Timelier Lung Cancer Surgery and Access to High-Volume Hospitals
April 17th 2025New research shows that Medicaid expansion was linked to a 2.1% increase in timely lung cancer surgeries and a 2.8% rise in procedures at high-volume hospitals, highlighting how policy changes can impact cancer care access.
Read More
